Volume 6 Issue 1
Jan.  2015
Turn off MathJax
Article Contents
Na XV, Yang JIAO, Xue-jun ZENG, Feng-chun ZHANG. Clinical Characteristics of 10 Cases with Polymyositis and Malignancy[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(1): 24-28. doi: 10.3969/j.issn.1674-9081.2015.01.005
Citation: Na XV, Yang JIAO, Xue-jun ZENG, Feng-chun ZHANG. Clinical Characteristics of 10 Cases with Polymyositis and Malignancy[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(1): 24-28. doi: 10.3969/j.issn.1674-9081.2015.01.005

Clinical Characteristics of 10 Cases with Polymyositis and Malignancy

doi: 10.3969/j.issn.1674-9081.2015.01.005
More Information
  • Corresponding author: JIAO Yang Tel: 010-69158221, E-mail:peterpumch@163.com
  • Received Date: 2014-02-28
  • Publish Date: 2015-01-30
  •   Objective  To summarize the clinical features of patients with polymyositis and malignancy.  Methods  We retrospectively reviewed the clinical records of patients with polymyositis and malignancy hospitalized at Peking Union Medical College Hospital from October 1989 to June 2013.  Results  Malignancy was identified in 2.4%(10/424)of patients with polymyositis in the hospital during the studied period. The median age of the 10 patients (3 males and 7 females) was 57 years.All patients had significant proximal muscle weakness. Difficulty in head-lifting, bucking, and hoarseness were each observed in one case. Interstitial lung disease, respiratory muscle involvement, and cardiac involvement were observed in 5, 2, and 6 patients, respectively. The most common types of cancer were lymphoma and lung cancer (3 cases each). Other types included esophageal, gastric, renal, and cervical cancers (1 case each). Malignancies in 7 cases were discovered within 1 year before or after polymyositis diagnosis. The initial demonstrations of malignancies included lymphadenectasis, cough and dyspnea, dysphagia, gross hematuria, and postmenopausal vaginal bleeding. Three asymptomatic patients were identified through screening based on positive feces occult blood test or lung mass. Five out of the 9 patients receiving adequate dose of glucocorticoid recovered completely from polymyositis within 1 month, whereas the remaining 4 patients improved but did not fully recover. Of the 4 patients, 3 patients achieved complete recovery after treatment for cancer.  Conclusions  Malignancy may interfere with the treatment response and prognosis of polymyositis, therefore patients with polymyositis should have a complete screening for the underlying malignancy. Early cancer treatment should be prescribed to better mitigate symptoms and manage conditions in patients with polymyositis and cancer.
  • loading
  • [1] Stertz G. Polymyositis[J]. Berl Klin Wochenschr, 1916, 53:489.
    [2] Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A populationbased cohort study[J]. Ann Intern Med, 2001, 134:1087-1095. doi:  10.7326/0003-4819-134-12-200106190-00008
    [3] Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study[J]. N Engl J Med, 1992, 326:363-367. doi:  10.1056/NEJM199202063260602
    [4] Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis:a nationwide cohort study in Denmark[J]. Cancer Causes Control, 1995, 6:9-13. doi:  10.1007/BF00051675
    [5] Limaye V, Luke C, Tucker G, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis[J]. Rheumatol Int, 2013, 33:965-971. doi:  10.1007/s00296-012-2489-y
    [6] Ungprasert P, Leeaphorn N, Hosiriluck N, et, al. Clinical features of inflammatory myopathies and their association with malignancy:a systematic review in asian population[J]. ISRN Rheumatol, 2013, 2013:509354. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600325/
    [7] Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis[J]. J Rheumatol, 1994, 21:1855-1859. https://www.ncbi.nlm.nih.gov/pubmed/7837150
    [8] Kannan MA, Sundaram C, Uppin M, et al. Incidence of malignancies in biopsy-proven inflammatory myophathy[J]. Neurol India, 2013, 6:152-155. https://www.ncbi.nlm.nih.gov/pubmed/23860177
    [9] Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study[J]. Ann Intern Med, 2001, 134:1087-1095. doi:  10.7326/0003-4819-134-12-200106190-00008
    [10] Antiochos BB, Brown LA, Li Z, et al.Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA[J]. J Rheumatol, 2009, 36:2704-2710. doi:  10.3899/jrheum.090549
    [11] Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications:a Scottish population-based cohort study[J]. Br J Cancer, 2001, 85:41-45. doi:  10.1054/bjoc.2001.1699
    [12] Chen YJ, Wu CY, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis:a nationwide cohort study in Taiwan[J]. Arthritis Res Ther, 2010, 12:R70. doi:  10.1186/ar2987
    [13] Bohan A, Peter JB. Polymyositis and dermatomyositis[J]. N Engl J Med, 1975, 292:344-347. doi:  10.1056/NEJM197502132920706
    [14] Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease:analysis of a series of 81 patients[J]. Lupus, 2005, 14:534-542. doi:  10.1191/0961203305lu2158oa
    [15] Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Clin Rheumatol, 2009, 28:639-646. doi:  10.1007/s10067-009-1110-6
    [16] Lundberg IE. The heart in dermatomyositis and polymyositis[J]. Rheumatology, 2006, 45:iv18-iv21. doi:  10.1093/rheumatology/kel311
    [17] Milisenda JC, Selva-O'Callaghan A, Grau JM. The diagnosis and classification of polymyositis[J]. J Autoimmun, 2014, 48-49:118-121. doi:  10.1016/j.jaut.2014.01.025
    [18] Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyosis and polymyositis:a population-based study[J]. Lancet, 2001, 357:96. doi:  10.1016/S0140-6736(00)03540-6
    [19] Zahr ZA, Baer AN. Malignancy in myositis[J]. Curr Rheumatol Rep, 2011, 13:208-215. doi:  10.1007/s11926-011-0169-7
    [20] Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology[J]. J Am Acad Dermatol, 1996, 34:824. doi:  10.1016/S0190-9622(96)90037-7
    [21] Sparsa A, Ciozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis:a study of 40 patients[J]. Arch Dermatol, 2002, 138:885.
    [22] Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis[J]. Lancet, 2003, 362:971-982. doi:  10.1016/S0140-6736(03)14368-1
    [23] Aggarwal R, Oddis CV. Therapeutic advances in myositis[J]. Curr Opin Rheumatol, 2012, 24:635-641. doi:  10.1097/BOR.0b013e328358ac72
    [24] Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis:effect of corticosteroids, methotrexate and azathioprine[J]. Arthritis Res Ther, 2012, 14:R22. doi:  10.1186/ar3704
    [25] Wang DX, Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis:a systematic literature review[J]. Clin Rheumatol, 2012, 31:801-806. doi:  10.1007/s10067-012-1940-5
    [26] Danieli MG, Gambini S, Pettinari L, et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study[J]. Autoimmun Rev, 2014, 13:1048-1054. doi:  10.1016/j.autrev.2014.08.023
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Article Metrics

    Article views (129) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return